<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04414397</url>
  </required_header>
  <id_info>
    <org_study_id>1878-702-008</org_study_id>
    <nct_id>NCT04414397</nct_id>
  </id_info>
  <brief_title>A Study Evaluating JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing in Adult Participants Over 22 Years Old</brief_title>
  <official_title>A Multicenter, Evaluator-blinded, Randomized, Parallel-group, Controlled Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the safety and effectiveness of Juvederm Voluma
      XC injectable gel in adult participants seeking correction of temple hollowing
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2020</start_date>
  <completion_date type="Anticipated">November 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 26, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants with at Least a 1-Point Improvement (Decrease) in Temple as Assessed by the Evaluating Investigator (EI) using the Allergan Temple Hollowing Scale (ATHS)</measure>
    <time_frame>Change from Baseline to Month 3</time_frame>
    <description>The Evaluating Investigator will assess the participant's temple hollowing using the ATHS 5-point scale where: 0=convex, rounded temple to 4=severe, deeply recessed, sunken appearance. A 1-point decrease from Baseline indicates improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants &quot;Improved&quot; or &quot;Much Improved&quot; as assessed by the Evaluating Investigator using the Global Aesthetic Improvement Scale (GAIS)</measure>
    <time_frame>Month 3</time_frame>
    <description>The Evaluating Investigator will assess the participant's temple area using the GAIS 5-point scale where: 2=much improved,
1=improved, 0=no change, -1=worse and-2=much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants &quot;Improved&quot; or &quot;Much Improved&quot; as self-assessed by participant using the Global Aesthetic Improvement Scale (GAIS)</measure>
    <time_frame>Month 3</time_frame>
    <description>Participant will assess temple area using the GAIS 5-point scale where: 2=much improved, 1=improved, 0=no change, -1=worse and-2=much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on FACE-Q Satisfaction with Facial Appearance questionnaire at Month 3</measure>
    <time_frame>Change from Baseline to Month 3</time_frame>
    <description>10-item questionnaire assessing satisfaction with various aspects of facial appearance. Participants respond to each item as: 1 Very Dissatisfied, 2 Somewhat Dissatisfied, 3 Somewhat Satisfied, 4 Very Satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Month 3 on participants responses on FACE-Q Satisfaction with Temples questionnaire</measure>
    <time_frame>Change from Baseline to Month 3</time_frame>
    <description>Multiple item questionnaire assessing satisfaction with various aspects of the temples. Participants respond to each item as: 1 Very Dissatisfied, 2 Somewhat Dissatisfied, 3 Somewhat Satisfied, 4 Very Satisfied</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">213</enrollment>
  <condition>Temple Hollowing</condition>
  <arm_group>
    <arm_group_label>VOLUMA® XC Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with JUVÉDERM VOLUMA® XC injectable gel in temple. Participants are eligible for touch up treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control- No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment is administered. Optional treatment at month 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JUVÉDERM VOLUMA® XC</intervention_name>
    <description>JUVÉDERM VOLUMA® XC injectable gel</description>
    <arm_group_label>VOLUMA® XC Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants in general good health

          -  Participants seeking improvement of temple hollowing

        Exclusion Criteria:

          -  Temple hollowing due to trauma, congenital malformations, or lipodystrophy, either
             congenital or acquired

          -  Experienced trauma to the temple area within 6 months before enrollment or has
             residual deficiencies, deformities, or scarring

          -  Temporal arteritis or history of temporal arteritis

          -  Temporomandibular joint dysfunction or any other jaw issues

          -  Recurrent temporal headaches such as temporal tendinitis migraine

          -  Active or recurrent inflammation or infection in either eye

          -  Tendency to develop hypertrophic scarring

          -  Active autoimmune disease

          -  History of anaphylaxis or allergy to lidocaine (or any amide-based anesthetics), HA
             products, or Streptococcal protein

          -  Current cutaneous or mucosal inflammatory or infectious processes (e.g. acne, herpes),
             abscess, an unhealed wound, or a cancerous or precancerous lesion, above the subnasal

          -  History of detached retina, retinal vascular occlusion (eg, vein or arterial
             occlusion), narrow angle glaucoma, neovascular eye disease, or severely
             impaired/absent eye function in 1 or both eyes

          -  Prior facial reconstructive surgeries, facelift, or browlift as well as surgeries on
             the temple area (eg, biopsy)

          -  Fat injection or permanent facial implants anywhere in the face

          -  Semipermanent soft-tissue filler treatment in the temple or mid-face within 36 months
             before enrollment

          -  Temporary dermal filler injections above the subnasale within 24 months before
             enrollment

          -  Mesotherapy or cosmetic facial procedures above the subnasale within 6 months before
             enrollment (examples of mesotherapy or cosmetic facial procedures are face-lift,
             laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, moderate
             or greater depth chemical peel, or other ablative procedures

          -  Injections in the nasolabial fold are acceptable only if done at least 3 months prior
             to enrollment

          -  Botulinum toxin treatment above the subnasale within 6 months before enrollment

          -  Has braces or other orthodontics or is planning such treatment during the study

          -  Not eligible for this study if participants have begun using any new over the counter
             or prescription oral or tropical, anti-wrinkle products above the subnasale within 30
             days before enrollment or are planning to begin using such products during the study.
             Participants who have been on a regimen of such products for at least 30 days are
             eligible for the study if they intend to continue their regimen throughout the study

          -  Is on a regimen of anti-coagulation therapy (eg, warfarin, clopidogrel)

          -  Has tattoos, piercings, facial hair, or scars above and including the subnasale that
             would interfere with visual assessment of the temple

          -  Females who are pregnant, nursing, or planning a pregnancy

          -  Plans a significant weight change (more than 10% of body weight) during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Abrams</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Registry Team</last_name>
    <phone>877-277-8566</phone>
    <email>IR-CTRegistration@Allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Skin Care and Laser Physicians of Beverly Hills</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Steve Yoelin M.D. Medical Associates, Inc.</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Steven Fagien, MD, PA</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bradenton Dermatologist</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>941-794-5432</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hevia Cosmetic Dermatology</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33484</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-443-9977</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baumann Cosmetic and Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Callender Center for Clinical Research</name>
      <address>
        <city>Glenn Dale</city>
        <state>Maryland</state>
        <zip>20769</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skincare Physicians</name>
      <address>
        <city>Chestnut Hill</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Williams Plastic Surgery Specialists</name>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <zip>12110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>518-786-7004</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rhoda S. Narins, MD, PC</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aesthetic Solutions, PA</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Practice of Brian S. Biesman, MD, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dallas Plastic Surgery Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jose Raul Montes Eyes &amp; Facial Rejuvenation-Torre Medica Aux</name>
      <address>
        <city>San Juan</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>787-777-0003</phone>
    </contact>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.investigatordatabank.org/</url>
    <description>To be considered as a site for current and future Allergan Clinical Trials, please register using the Investigator Databank link.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Allergan will share de-identified patient-level data and study-level data including protocols and clinical study reports for phase 2 - 4 trials completed after 2008 that are registered to ClinicalTrials.gov or EudraCT, have received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published. To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes. More information can be found on http://www.allerganclinicaltrials.com/.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After having received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published..</ipd_time_frame>
    <ipd_access_criteria>To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes.</ipd_access_criteria>
    <ipd_url>http://www.allerganclinicaltrials.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

